Cardiovascular Drugs Practice Questions

Q: All of the following statements about Ranolazine are true, except?

Hypotension is an established adverse effect.. **Explanation:** **Ranolazine** is a novel antianginal agent with a unique mechanism of action. The correct answer is **D** because, unlike traditional antianginals (Nitrates, Beta-blockers, CCBs), **Ranolazine does not significantly affect heart rate or blood pressure.** Therefore, hypotension is not an established adverse effect. **Breakdown of Options:** * **Option A (True):** Ranolazine is chemically a **piperazine derivative**. It works by inhibiting the **late inward sodium current ($I_{Na}$)** in myocardial cells. This prevents calcium overload via the $Na^+/Ca^{2+}$ exchanger, improving diastolic relaxation and subendocardial perfusion without altering hemodynamics. * **Option B (True):** According to recent guidelines, Ranolazine is approved as a **first-line agent** for chronic stable angina, either as monotherapy or in combination with other drugs. * **Option C (True):** Clinical trials (like CARISA and MERLIN-TIMI 36) have shown that Ranolazine can **reduce HbA1c levels** in diabetic patients, making it a preferred choice for anginal patients with comorbid Diabetes Mellitus. **High-Yield Clinical Pearls for NEET-PG:** * **ECG Change:** Ranolazine causes **dose-dependent QT interval prolongation** (via inhibition of $I_{Kr}$), yet it paradoxically has a low risk of Torsades de Pointes. * **Metabolism:** It is primarily metabolized by **CYP3A4**; hence, it is contraindicated with potent inhibitors like Ketoconazole or Clarithromycin. * **Side Effects:** Most common side effects include dizziness, headache, constipation, and nausea. * **Key Benefit:** It is the drug of choice for angina patients who have low baseline blood pressure or heart rate, as it does not lower them further.

Q: Nesiritide is broken down by which enzyme?

Endopeptidase. **Explanation:** **Nesiritide** is a recombinant form of human **B-type Natriuretic Peptide (BNP)**. It is used in the management of acutely decompensated heart failure to reduce pulmonary capillary wedge pressure and improve dyspnea through its potent vasodilatory and natriuretic effects. 1. **Why Endopeptidase is correct:** Nesiritide, being a peptide, is primarily cleared from the circulation via two mechanisms: binding to natriuretic peptide receptors (NPR-C) followed by cellular internalization, and enzymatic degradation. The specific enzyme responsible for its proteolytic cleavage is **Neutral Endopeptidase (NEP)**, also known as **Neprilysin**. This enzyme breaks the peptide bonds of various endogenous vasoactive peptides, including BNP, ANP, and bradykinin. 2. **Why the other options are incorrect:** * **Angiotensin-converting enzyme (ACE):** While ACE is a peptidyl dipeptidase, its primary role is converting Angiotensin I to Angiotensin II and inactivating bradykinin. It does not play a significant role in the metabolism of BNP. * **Vasopeptidase:** This is not a single enzyme but a class of drugs (e.g., Omapatrilat) that inhibits both ACE and Neutral Endopeptidase. * **Amidase:** These enzymes catalyze the hydrolysis of an amide or peptide bond but are typically associated with the metabolism of drugs like lidocaine or certain prodrugs, not the physiological degradation of natriuretic peptides. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Nesiritide increases intracellular **cGMP**, leading to smooth muscle relaxation. * **Clinical Use:** Used in **Acute Decompensated Heart Failure (ADHF)** with dyspnea at rest. * **Major Side Effect:** Dose-related **hypotension** is the most common adverse effect. * **Related Drug:** **Sacubitril** is a Neprilysin inhibitor used in HFrEF (combined with Valsartan as ARNI) to prevent the breakdown of endogenous BNP.

Q: Which of the following beta-blockers has membrane stabilizing action?

Propranolol. **Explanation:** **Membrane Stabilizing Activity (MSA)**, also known as a "quinidine-like effect" or local anesthetic activity, refers to the ability of certain beta-blockers to inhibit the initiation and propagation of action potentials by blocking voltage-gated sodium channels. 1. **Why Propranolol is Correct:** **Propranolol** is the prototypical non-selective beta-blocker with significant MSA. At high concentrations, it reduces the rate of rise of the cardiac action potential (Phase 0). While this property is rarely clinically relevant at standard doses, it becomes highly significant in **toxicology** (overdose), leading to QRS widening and arrhythmias. Other drugs with MSA include Pindolol, Acebutolol, and Metoprolol (weak). 2. **Analysis of Incorrect Options:** * **Nadolol:** A long-acting, non-selective beta-blocker that lacks MSA and has low lipid solubility. * **Atenolol:** A cardioselective ($\beta_1$) blocker that is hydrophilic and lacks MSA. It is primarily excreted unchanged by the kidneys. * **Nebivolol:** A highly selective $\beta_1$ blocker that also promotes vasodilation via **Nitric Oxide (NO)** release. It does not possess MSA. **High-Yield Clinical Pearls for NEET-PG:** * **Lipid Solubility:** Propranolol is highly lipophilic, allowing it to cross the blood-brain barrier (useful for tremors and prophylaxis of migraine) but also causing CNS side effects like vivid dreams. * **Intrinsic Sympathomimetic Activity (ISA):** Remember **Pindolol** and **Acebutolol** for having partial agonist activity (useful in patients with bradycardia). * **Water Soluble Beta-blockers:** Atenolol and Nadolol (mnemonic: **A**ny **N**ew **S**oluble = Atenolol, Nadolol, Sotalol). * **Beta-blocker with longest half-life:** Nadolol; **Shortest half-life:** Esmolol (metabolized by RBC esterases).

Q: What is the treatment of choice for congestive heart failure with hypertension?

ACE inhibitors. **Explanation:** **ACE inhibitors (ACEIs)** are the treatment of choice for patients with coexisting congestive heart failure (CHF) and hypertension [1]. The underlying medical concept is their ability to provide **balanced vasodilation** (reducing both preload and afterload) and, more importantly, to inhibit the **Renin-Angiotensin-Aldosterone System (RAAS)** [2]. By blocking Angiotensin II, ACEIs prevent cardiac remodeling and fibrosis, which are key drivers of heart failure progression [2]. They are one of the few drug classes proven to **reduce mortality** in CHF [1]. **Why other options are incorrect:** * **Alpha-blockers:** These are not first-line for CHF. While they lower blood pressure, they can cause reflex tachycardia and fluid retention, potentially worsening heart failure symptoms. * **Calcium Channel Blockers (CCBs):** Non-dihydropyridines (Verapamil/Diltiazem) are contraindicated in CHF due to their negative inotropic effects. While Amlodipine is safe, it does not provide the mortality benefits seen with ACEIs. * **Nitrates:** These are primarily venodilators (reducing preload) [3]. While useful in acute heart failure or in combination with Hydralazine (especially in specific populations), they are not the primary first-line monotherapy for managing chronic CHF with hypertension [3]. **High-Yield Clinical Pearls for NEET-PG:** * **First-line triad for HFrEF:** ACEIs (or ARBs/ARNIs), Beta-blockers, and Aldosterone antagonists [1]. * **Side Effects:** Watch for **dry cough** (due to bradykinin accumulation) and **angioedema**. If a cough develops, switch the patient to an ARB (Losartan). * **Contraindications:** ACEIs are strictly contraindicated in **pregnancy** (teratogenic) and **bilateral renal artery stenosis**.

Q: First-dose hypotension is caused by which of the following drugs?

Prazosin. **Explanation:** **Prazosin** is the correct answer because it is a selective **alpha-1 (α1) adrenergic blocker**. It causes significant peripheral vasodilation in both arterioles and veins. The "first-dose effect" occurs because the initial dose can cause a sudden, precipitous drop in blood pressure, leading to orthostatic hypotension and syncope. This happens because the drug inhibits the compensatory vasoconstriction required when a patient moves from a supine to a standing position. **Analysis of Incorrect Options:** * **Clonidine:** An alpha-2 agonist that acts centrally to decrease sympathetic outflow. While it lowers BP, it is more notorious for **rebound hypertension** upon sudden withdrawal rather than first-dose hypotension. * **Sodium Nitroprusside:** A potent parenteral vasodilator used in hypertensive emergencies. While it causes rapid hypotension, it is administered via titrated IV infusion in a controlled setting, not as an oral "first dose" phenomenon. * **Propranolol:** A non-selective beta-blocker. It reduces cardiac output and renin release. It does not typically cause acute postural hypotension; in fact, it can sometimes cause initial peripheral vasoconstriction due to unopposed alpha activity. **High-Yield Clinical Pearls for NEET-PG:** * **Prevention:** To minimize the first-dose effect, the initial dose of Prazosin should be small (1 mg) and administered **at bedtime** ("Bedtime dose"). * **Other Drugs:** Other alpha-blockers like Terazosin and Doxazosin also exhibit this effect. * **Indication:** Apart from hypertension, Prazosin is used in **Benign Prostatic Hyperplasia (BPH)** to relax the bladder neck and in **Raynaud’s phenomenon**.

Q: Digoxin induced arrhythmias are treated by all the following except?

Quinidine. **Explanation:** **Quinidine (Option D)** is the correct answer because it is strictly **contraindicated** in digoxin toxicity. Quinidine increases plasma digoxin levels by displacing it from tissue binding sites and reducing its renal clearance. Furthermore, both drugs can cause additive depression of the AV node, potentially worsening heart block. **Why other options are used:** * **Lidocaine (Option A):** This is the drug of choice for digoxin-induced ventricular arrhythmias (PVCs, ventricular tachycardia). It suppresses ventricular automaticity without significantly affecting AV conduction. * **Phenytoin (Option B):** Specifically useful for digoxin-induced atrial tachyarrhythmias with AV block. It suppresses abnormal automaticity while simultaneously improving AV conduction. * **Atropine (Option C):** Used to treat digoxin-induced symptomatic bradycardia or high-grade AV block by blocking the excessive vagal (parasympathetic) tone caused by digitalis. **Clinical Pearls for NEET-PG:** 1. **Most common arrhythmia:** Ventricular Bigeminy (PVCs). 2. **Most characteristic arrhythmia:** Atrial Tachycardia with variable AV block. 3. **Electrolyte imbalances:** Hypokalemia, hypomagnesemia, and hypercalcemia predispose to toxicity. However, **Hyperkalemia** is a marker of severe acute toxicity (due to Na+/K+ ATPase inhibition). 4. **Specific Antidote:** Digoxin Immune Fab (Digibind) is the definitive treatment for life-threatening toxicity. 5. **Drugs increasing Digoxin levels:** Quinidine, Verapamil, Amiodarone, and Erythromycin.

Question 1

All of the following statements about Ranolazine are true, except?

Accepted Answer

Hypotension is an established adverse effect.

Answer

Piperazine derived antianginal agent.

Answer

May be used as first line agent in chronic angina.

Answer

May improve glycemic control.

Question 2

Which drug is contraindicated in severe hypertriglyceridemia?

Accepted Answer

Niacin

Answer

Fibrates

Answer

Simvastatin

Answer

Cholestyramine

Question 3

Nesiritide is broken down by which enzyme?

Accepted Answer

Endopeptidase

Answer

Angiotensin converting enzyme

Answer

Vasopeptidase

Answer

Amidase

Question 4

Which of the following beta-blockers has membrane stabilizing action?

Accepted Answer

Propranolol

Answer

Nadolol

Answer

Atenolol

Answer

Nebivolol

Question 5

Which of the following drugs does not cause postural hypotension?

Accepted Answer

ACE inhibitor

Answer

Prazosin

Answer

Phentolamine

Answer

Levodopa

Question 6

Which of the following drugs is capable of maintaining blood levels for 24 hours after a single administration but has useful antianginal effects lasting only about 10 hours?

Accepted Answer

Nitroglycerine (transdermal)

Answer

Amyl nitrite

Answer

Isosorbide mononitrate

Answer

Nitroglycerine (sublingual)

Question 7

What is the treatment of choice for congestive heart failure with hypertension?

Accepted Answer

ACE inhibitors

Answer

Alpha-blockers

Answer

Calcium channel blockers

Answer

Nitrates

Question 8

First-dose hypotension is caused by which of the following drugs?

Accepted Answer

Prazosin

Answer

Clonidine

Answer

Sodium nitroprusside

Answer

Propranolol

Question 9

What is the primary role of nitrates in congestive cardiac failure?

Accepted Answer

Decrease preload

Answer

Direct inotropic action

Answer

Decrease afterload

Answer

Coronary vasodilatation

Question 10

Digoxin induced arrhythmias are treated by all the following except?

Accepted Answer

Quinidine

Answer

Lidocaine

Answer

Phenytoin

Answer

Atropine

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?